416 related articles for article (PubMed ID: 21205913)
21. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
22. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
Cheng HC; Incardona J
J Pharmacol Toxicol Methods; 2009; 60(2):174-84. PubMed ID: 19524054
[TBL] [Abstract][Full Text] [Related]
23. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
24. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin.
Milnes JT; Dempsey CE; Ridley JM; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
FEBS Lett; 2003 Jul; 547(1-3):20-6. PubMed ID: 12860380
[TBL] [Abstract][Full Text] [Related]
25. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
Dumotier BM; Deurinck M; Yang Y; Traebert M; Suter W
Pharmacol Ther; 2008 Aug; 119(2):152-9. PubMed ID: 18462801
[TBL] [Abstract][Full Text] [Related]
26. Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
Hong HK; Park MH; Lee BH; Jo SH
Biochem Biophys Res Commun; 2010 Apr; 394(3):536-41. PubMed ID: 20211602
[TBL] [Abstract][Full Text] [Related]
27. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
28. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
29. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
30. Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.
Vigneault P; Bourgault S; Kaddar N; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
Eur J Pharmacol; 2012 Apr; 681(1-3):68-74. PubMed ID: 22366430
[TBL] [Abstract][Full Text] [Related]
31. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of gefitinib-induced QT prolongation.
Jie LJ; Li YD; Zhang HQ; Mao L; Xie HB; Zhou FG; Zhou TL; Xie D; Lin JL; Li GY; Cai BN; Zhang YH; Wang Y
Eur J Pharmacol; 2021 Nov; 910():174441. PubMed ID: 34474028
[TBL] [Abstract][Full Text] [Related]
33. Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Shopp GM; Helson L; Bouchard A; Salvail D; Majeed M
Anticancer Res; 2014 Sep; 34(9):4733-40. PubMed ID: 25202051
[TBL] [Abstract][Full Text] [Related]
34. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
[TBL] [Abstract][Full Text] [Related]
35. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Zünkler BJ
Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
[TBL] [Abstract][Full Text] [Related]
37. The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage.
Lamothe SM; Guo J; Li W; Yang T; Zhang S
J Biol Chem; 2016 Sep; 291(39):20387-401. PubMed ID: 27502273
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
39. Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.
Vigneault P; Pilote S; Patoine D; Simard C; Drolet B
Pharmacol Res; 2012 Jul; 66(1):60-5. PubMed ID: 22465688
[TBL] [Abstract][Full Text] [Related]
40. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
